NASDAQ:ARDXArdelyx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ardelyx Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.20 -0.31 (-4.13 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$7.11Now: $7.20▼$7.6650-Day Range$5.37MA: $7.09▼$8.0752-Week Range$2.10Now: $7.20▼$8.81Volume420,178 shsAverage Volume657,659 shsMarket Capitalization$640.30 millionP/E RatioN/ADividend YieldN/ABeta1.89 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Ardelyx has a potential upside of 66.7% from its current price of $7.20.Amount of Analyst CoverageArdelyx has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesArdelyx has received 473 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArdelyx has received 418 “underperform” votes. (Add your “underperform” vote.)Community SentimentArdelyx has received 53.09% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote “Outperform” if you believe ARDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $392,452.00 in company stock.Percentage Held by InsidersOnly 15.31% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions86.08% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($1.05) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDX Previous Symbol CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone510-745-1700Debt Debt-to-Equity Ratio0.26 Current Ratio9.76 Quick Ratio9.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.28 million Price / Sales121.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.89 per share Price / Book3.81Profitability EPS (Most Recent Fiscal Year)($1.47) Net Income$-94,940,000.00 Net Margins-1,403.90% Return on Equity-77.23% Return on Assets-48.46%Miscellaneous Employees88 Outstanding Shares88,930,000Market Cap$640.30 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:ARDX Rates by TradingView Receive ARDX News and Ratings via Email Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Ardelyx (NASDAQ:ARDX) Frequently Asked Questions How has Ardelyx's stock been impacted by COVID-19 (Coronavirus)? Ardelyx's stock was trading at $5.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARDX stock has increased by 20.4% and is now trading at $7.20. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ardelyx? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ardelyx. When is Ardelyx's next earnings date? Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Ardelyx. How were Ardelyx's earnings last quarter? Ardelyx Inc (NASDAQ:ARDX) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the Zacks' consensus estimate of ($0.25) by $0.00. The biopharmaceutical company earned $1.21 million during the quarter, compared to the consensus estimate of $0.90 million. Ardelyx had a negative return on equity of 77.23% and a negative net margin of 1,403.90%. View Ardelyx's earnings history. What price target have analysts set for ARDX? 5 analysts have issued 12-month price targets for Ardelyx's shares. Their forecasts range from $9.00 to $15.00. On average, they anticipate Ardelyx's share price to reach $12.00 in the next year. This suggests a possible upside of 66.7% from the stock's current price. View analysts' price targets for Ardelyx. Has Ardelyx been receiving favorable news coverage? Media headlines about ARDX stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ardelyx earned a coverage optimism score of 0.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutArdelyx. Who are some of Ardelyx's key competitors? Some companies that are related to Ardelyx include HUTCHISON CHINA/S (HCM), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Taro Pharmaceutical Industries (TARO), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Turning Point Therapeutics (TPTX), Karuna Therapeutics (KRTX), Ra Pharmaceuticals (RARX), TG Therapeutics (TGTX), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS) and Epizyme (EPZM). View all competitors. What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Gilead Sciences (GILD), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), BioCryst Pharmaceuticals (BCRX), ImmunoGen (IMGN), SCYNEXIS (SCYX), AbbVie (ABBV), NVIDIA (NVDA) and Rigel Pharmaceuticals (RIGL). Who are Ardelyx's key executives? Ardelyx's management team includes the following people: Mr. Michael G. Raab, Pres, CEO & Director (Age 55, Pay $988k)Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 56, Pay $596k)Mr. David Rosenbaum, Chief Devel. Officer (Age 59, Pay $617.25k)Mr. Keith Santorelli, Acting Principal Financial & Accounting Officer (Age 46)Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 57) What is Ardelyx's stock symbol? Ardelyx trades on the NASDAQ under the ticker symbol "ARDX." Who are Ardelyx's major shareholders? Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (7.22%), BlackRock Inc. (7.89%), Redmile Group LLC (4.39%), Ikarian Capital LLC (1.64%), State Street Corp (1.30%) and Geode Capital Management LLC (1.13%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Mark Kaufmann, Michael Raab and Scott D Sandell. View institutional ownership trends for Ardelyx. Which institutional investors are selling Ardelyx stock? ARDX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Squarepoint Ops LLC, Redmile Group LLC, Invesco Ltd., Wexford Capital LP, UBS Group AG, DAFNA Capital Management LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann, and Michael Raab. View insider buying and selling activity for Ardelyx. Which institutional investors are buying Ardelyx stock? ARDX stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., BlackRock Inc., Ikarian Capital LLC, Morgan Stanley, Morgan Stanley, State Street Corp, Bailard Inc., and AQR Capital Management LLC. View insider buying and selling activity for Ardelyx. How do I buy shares of Ardelyx? Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ardelyx's stock price today? One share of ARDX stock can currently be purchased for approximately $7.20. How big of a company is Ardelyx? Ardelyx has a market capitalization of $640.30 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe. What is Ardelyx's official website? The official website for Ardelyx is www.ardelyx.com. How can I contact Ardelyx? Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
